MetaVia Inc.
MTVA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MTVA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MTVA
MetaVia Inc. (MTVA) is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases, currently advancing DA-1241 and DA-1726 through clinical trials while facing significant financial uncertainty.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for MetaVia Inc..
MetaVia Inc. (MTVA) is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases, currently advancing DA-1241 and DA-1726 through clinical trials while facing significant financial uncertainty.
- MetaVia is conducting a Phase 2a clinical trial for DA-1241 and a Phase 1 clinical trial for DA-1726 [sec_mda · as of 2025-05-14].
- As of June 30, 2026, the company reported cash & equivalents of $12.6M, a net loss of $5.3M, and shareholders' equity of $5.3M [sec].
- The company has incurred net losses and negative cash flows from operations, with a net loss of $4.3M for the three months ended March 31, 2026 [sec_mda · as of 2026-05-14].
- MetaVia has expressed substantial doubt about its ability to continue as a going concern within one year from the issuance of its unaudited condensed consolidated financial statements [sec_mda · as of 2026-05-14].
- The company plans to fund operations through equity offerings, debt financing, warrant exercises, or collaborations, but there is no assurance of obtaining such financing on acceptable terms [sec_mda · as of 2026-05-14].
What works
- MetaVia has two product candidates in clinical development (DA-1241 Phase 2a and DA-1726 Phase 1), indicating ongoing pipeline progress [sec_mda · as of 2025-05-14].
- The company continues to invest in R&D despite financial constraints, suggesting commitment to advancing its programs [sec_mda · as of 2026-05-14].
What to weigh
- MetaVia has a going concern uncertainty, with substantial doubt about its ability to continue operations within one year [sec_mda · as of 2026-05-14].
- The company has a history of net losses and negative cash flows, with a net loss of $4.3M for the three months ended March 31, 2026 [sec_mda · as of 2026-05-14].
- MetaVia's ability to raise additional capital is uncertain, and failure to do so could force it to slow or stop clinical trials [sec_mda · as of 2026-08-06].
- Clinical trial delays could increase costs and jeopardize regulatory approval and revenue generation [sec_mda · as of 2026-03-26].
From the filings
Quoted directly from source documents.
The company has a going concern uncertainty within one year.
“These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these unaudited condensed consolidated financial statements.”
SEC MD&A · May 14, 2026
The company reported a net loss of $4.3 million for the three months ended March 31, 2026.
“of $4.3 million for the three months ended March 31, 2026.”
SEC MD&A · May 14, 2026
The company plans to fund operations through various sources but cannot assure availability.
“We plan to continue to fund our operations from equity offerings, debt financing, exercise of existing warrants , or other sources, potentially including collaborations, out-licensing and other similar arrangements. However, there can be no assurance that we will be able to obtain any sources of financing on acceptable terms, or at all”
SEC MD&A · May 14, 2026
Clinical trial delays could harm the business.
“Any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.”
SEC MD&A · March 26, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern within one year [sec_mda · as of 2026-05-14]
- Capital raising risk — No assurance of obtaining financing on acceptable terms; may need to slow or stop trials [sec_mda · as of 2026-08-06]
- Clinical trial delays — Delays could increase costs and jeopardize regulatory approval and revenue [sec_mda · as of 2026-03-26]
- History of losses — Continued net losses and negative cash flows from operations expected [sec_mda · as of 2026-05-14]
What to watch
- Ability to raise additional capital through equity, debt, or partnerships [sec_mda · as of 2026-05-14]
- Progress and results of Phase 2a trial for DA-1241 and Phase 1 trial for DA-1726 [sec_mda · as of 2025-05-14]
- Any updates on going concern resolution or financial runway extension [sec_mda · as of 2026-05-14]
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run MetaVia Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MetaVia Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
10.2 months
D/E 0.95 · 0% dilution
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$68K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 33,635 | $40K |
| jane street group, llc | 10,903 | $13K |
| vanguard fiduciary trust co | 6,940 | $8K |
| vanguard capital management llc | 4,444 | $5K |
| blackrock, inc. | 479 | $575 |
| brown brothers harriman & co | 2 | $2 |
| danske bank a/s | 2 | $2 |
| ubs group ag | 1 | $1 |
Short Interest
as of Apr 21, 2026- % of float
- 1.7%
- Days to cover
- 0.3
- Shares short
- 56,743
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MTVA short interestGovernance
Frequently asked questions
What is the AI investment thesis for MetaVia Inc.?
MetaVia Inc. (MTVA) is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases, currently advancing DA-1241 and DA-1726 through clinical trials while facing significant financial uncertainty.
What is MetaVia Inc.'s lead drug candidate?
MetaVia Inc.'s most advanced tracked candidate is da-1241 (Phase 2) for MASH and Type 2 Diabetes Mellitus.
Who is the CEO of MetaVia Inc.?
Mr. Hyung Heon Kim is the chief executive officer of MetaVia Inc. (MTVA).
Where is MetaVia Inc. headquartered?
MetaVia Inc. (MTVA) is headquartered in Cambridge, MA, United States.
What therapeutic areas does MetaVia Inc. focus on?
MetaVia Inc. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.